Oxford Nanopore Technologies Ltd

MinION is a pocket-sized portable device used for real-time biological analysis. It is adaptable to the analysis of DNA, RNA, or proteins. MinION's simple workflow allows end-to-end experiments in many environments.

Start using MinION

PromethION combines MinION's simplicity of use with greater workflow flexibility through scale and a modular design. Increase throughput by analysing the same sample simultaneously in multiple flow cells, or run different samples concurrently.

The GridION system, currently in development, is a scalable real-time analysis system designed to analyse single molecules such as DNA, RNA and proteins.

Metrichor provides a cloud-based platform for real time analysis of data from nanopore devices. Applications available through Metrichor will expand with the ultimate goal of enabling the analysis of any living thing, by any user, in any environment.

Start using MinION

Register to join the MinION Access Programme (MAP) to use MinION – our portable, real-time molecular analysis tool.

Executive - Clive G. Brown
Clive G. Brown
Clive G. Brown
go back

Clive is Chief Technology Officer at Oxford Nanopore. On the Executive team, he is responsible for all of the Company’s product-development activities. Clive leads the specification and design of the Company’s nanopore-based sensing platform, including strand DNA/RNA sequencing and protein-sensing applications with a strong focus on scientific excellence and successful adoption by the scientific community.

Clive joined Oxford Nanopore from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of 'next generation' DNA sequencing platforms. This involved helping to set up the world’s largest single installation of Illumina (formerly Solexa) Genome Analyzers in a production sequencing environment, initially used to pioneer the 1000 genomes project.

From early 2003 he was Director of Computational Biology and IT at Solexa Ltd, where he was central to the development and commercialisation of the Genome Analyzer (GA). Solexa was sold to Illumina for $650m in early 2007 after the successful placement and adoption of 12 instruments. The Solexa technology, now commercialised by Illumina, is the market-leading DNA sequencing technology driving the renaissance in DNA-based discovery.

He has a strong background in computer science and genetics/molecular biology and manages interdisciplinary teams including mechanical engineering, electronics, physics, surface chemistry, electrophysiology, software engineering and applications (of the technology). Clive applies modern agile management techniques to the entire product-development lifecycle.

Clive has also held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations. He has worked at the interface between computing and science, ranging from genetics to proteomics. He holds degrees in Genetics and Computational Biology from the University of York.